OncoCyte Corp expected to post a loss of $1.14 a share - Earnings Preview

Insight Molecular Diagnostics

29/03/2024 12:50

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a fall
in
quarterly revenue when it reports  results on April 1
(estimated) for the period ending December 31 2023
    * The Irvine California-based  company is expected to report
a
71.8% decrease in revenue to $316.67 thousand from $1.12 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for OncoCyte Corp is for a
loss of
$1.14 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$3.80​, above​ its last closing price of $2.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.00       -1.01      -0.81     Beat    19.6
 Jun. 30 2023  -0.68       -1.30      -1.07     Beat    17.7
 Mar. 31 2023  -1.31       -1.84      0.40      Beat    121.7​
 Dec. 31 2022              -1.88      -8.00     Missed  -324.6
 ​​Sep.        -2.28       -2.26      -1.60     Beat    29.1
 30 2022                                                
 Jun. 30 2022  -2.32       -2.39      -1.40     Beat    41.3​
 Mar. 31 2022  -2.34       -2.40      -2.20     Beat    8.3
 Dec. 31 2021  -2.80       -2.54      -2.40     Beat    5.6
 This summary was machine generated March 29 at 12:50 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)